JP Morgan Private Wealth Advisors’s Aimmune Therapeutics AIMT Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-19,214	Closed	-$662K	–	1759
2020 Q3	$662K	Sell	19,214 -5,961	-24%	-$127K	﹤0.01%	1046
2020 Q2	$421K	Buy	25,175 +2,384	+10%	+$40.5K	﹤0.01%	1179
2020 Q1	$329K	Buy	22,791 +7,759	+52%	+$198K	﹤0.01%	1099
2019 Q4	$503K	Sell	15,032 -4,371	-23%	-$122K	﹤0.01%	1050
2019 Q3	$406K	Buy	19,403 +8,433	+77%	+$172K	﹤0.01%	1070
2019 Q2	$228K	Buy	10,970 +293	+3%	+$6.03K	﹤0.01%	1256
2019 Q1	$239K	Buy	+10,677	New	+$251K	﹤0.01%	1314
2018 Q1	–	Sell	-5,346	Closed	-$202K	–	1410
2017 Q4	$202K	Buy	+5,346	New	+$172K	﹤0.01%	1187
2016 Q4	–	Sell	-37,050	Closed	-$556K	–	1314
2016 Q3	$556K	Sell	37,050 -8,700	-19%	-$117K	0.01%	755
2016 Q2	$495K	Buy	+45,750	New	+$622K	﹤0.01%	784

JP Morgan Private Wealth Advisors's AIMT Position: Q4 2020 in Review

JP Morgan Private Wealth Advisors sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 19,214 shares — an estimated $662K sold.

JP Morgan Private Wealth Advisors first reported a position in AIMT in Q2 2016 and held it in 10 quarters. The position peaked at $662K in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

JP Morgan Private Wealth Advisors reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
JP Morgan Private Wealth Advisors sold 19,214 Aimmune Therapeutics shares in Q4 2020, an estimated $662K.
JP Morgan Private Wealth Advisors first reported a position in Aimmune Therapeutics in Q2 2016 and held it in 10 quarters.
JP Morgan Private Wealth Advisors's Aimmune Therapeutics position peaked at $662K in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.